BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shen YC, Lin ZZ, Hsu CH, Hsu C, Shao YY, Cheng AL. Clinical trials in hepatocellular carcinoma: an update. Liver Cancer 2013;2:345-64. [PMID: 24400222 DOI: 10.1159/000343850] [Cited by in Crossref: 43] [Cited by in F6Publishing: 47] [Article Influence: 5.4] [Reference Citation Analysis]
Number Citing Articles
1 Huang CY, Tai WT, Wu SY, Shih CT, Chen MH, Tsai MH, Kuo CW, Shiau CW, Hung MH, Chen KF. Dovitinib Acts As a Novel Radiosensitizer in Hepatocellular Carcinoma by Targeting SHP-1/STAT3 Signaling. Int J Radiat Oncol Biol Phys 2016;95:761-71. [PMID: 26960749 DOI: 10.1016/j.ijrobp.2016.01.016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
2 Shen J, Wang S, Siegel AB, Remotti H, Wang Q, Sirosh I, Santella RM. Genome-Wide Expression of MicroRNAs Is Regulated by DNA Methylation in Hepatocarcinogenesis. Gastroenterol Res Pract 2015;2015:230642. [PMID: 25861255 DOI: 10.1155/2015/230642] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
3 Fu Y, Li F, Zhang P, Liu M, Qian L, Lv F, Cheng W, Hou R. Myrothecine A modulates the proliferation of HCC cells and the maturation of dendritic cells through downregulating miR-221. Int Immunopharmacol 2019;75:105783. [PMID: 31376622 DOI: 10.1016/j.intimp.2019.105783] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
4 Liao CY, Lee CC, Tsai CC, Hsueh CW, Wang CC, Chen IH, Tsai MK, Liu MY, Hsieh AT, Su KJ. Novel Investigations of Flavonoids as Chemopreventive Agents for Hepatocellular Carcinoma. Biomed Res Int. 2015;2015:840542. [PMID: 26858957 DOI: 10.1155/2015/840542] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
5 Xia H, Huang Z, Liu S, Zhao X, He R, Wang Z, Shi W, Chen W, Li Z, Yu L, Huang P, Kang P, Su Z, Xu Y, Yam JWP, Cui Y. Exosomal Non-Coding RNAs: Regulatory and Therapeutic Target of Hepatocellular Carcinoma. Front Oncol 2021;11:653846. [PMID: 33869059 DOI: 10.3389/fonc.2021.653846] [Reference Citation Analysis]
6 Xiong A, Spyrou A, Forsberg-Nilsson K. Involvement of Heparan Sulfate and Heparanase in Neural Development and Pathogenesis of Brain Tumors. Adv Exp Med Biol 2020;1221:365-403. [PMID: 32274718 DOI: 10.1007/978-3-030-34521-1_14] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
7 Falasca M, Maffucci T. Targeting p110gamma in gastrointestinal cancers: attack on multiple fronts. Front Physiol 2014;5:391. [PMID: 25360116 DOI: 10.3389/fphys.2014.00391] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
8 Buijs N, Oosterink JE, Jessup M, Schierbeek H, Stolz DB, Houdijk AP, Geller DA, van Leeuwen PA. A new key player in VEGF-dependent angiogenesis in human hepatocellular carcinoma: dimethylarginine dimethylaminohydrolase 1. Angiogenesis 2017;20:557-65. [PMID: 28741166 DOI: 10.1007/s10456-017-9567-4] [Cited by in Crossref: 38] [Cited by in F6Publishing: 44] [Article Influence: 7.6] [Reference Citation Analysis]
9 Coleman SJ, Grose RP, Kocher HM. Fibroblast growth factor family as a potential target in the treatment of hepatocellular carcinoma. J Hepatocell Carcinoma 2014;1:43-54. [PMID: 27508175 DOI: 10.2147/JHC.S48958] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
10 Yang W, Feng Q, Li M, Su J, Wang P, Wang X, Yin Y, Wang X, Zhao M. Sinomenine Suppresses Development of Hepatocellular Carcinoma Cells via Inhibiting MARCH1 and AMPK/STAT3 Signaling Pathway. Front Mol Biosci 2021;8:684262. [PMID: 34179090 DOI: 10.3389/fmolb.2021.684262] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Liu C, Wu H, Mao Y, Chen W, Chen S. Exosomal microRNAs in hepatocellular carcinoma. Cancer Cell Int 2021;21:254. [PMID: 33964930 DOI: 10.1186/s12935-021-01941-9] [Reference Citation Analysis]
12 Llovet JM, Villanueva A, Lachenmayer A, Finn RS. Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol. 2015;12:408-424. [PMID: 26054909 DOI: 10.1038/nrclinonc.2015.103] [Cited by in Crossref: 260] [Cited by in F6Publishing: 261] [Article Influence: 37.1] [Reference Citation Analysis]
13 Yu LX, Ling Y, Wang HY. Role of nonresolving inflammation in hepatocellular carcinoma development and progression. NPJ Precis Oncol 2018;2:6. [PMID: 29872724 DOI: 10.1038/s41698-018-0048-z] [Cited by in Crossref: 75] [Cited by in F6Publishing: 82] [Article Influence: 18.8] [Reference Citation Analysis]
14 Storme J, Tosh DK, Gao ZG, Jacobson KA, Stove CP. Probing structure-activity relationship in β-arrestin2 recruitment of diversely substituted adenosine derivatives. Biochem Pharmacol 2018;158:103-13. [PMID: 30292756 DOI: 10.1016/j.bcp.2018.10.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
15 Luo T, Zhang FX, Zhao K, Gao HY, Zhang SG, Wang L, Dou GF, Liu T, Yu M, Zhan YQ, Chen H, Yang XM, Li CY. Preclinical Pharmacokinetics, Tissue Distribution, and Primary Safety Evaluation of Indo5, a Novel Selective Inhibitor of c-Met and Trks. Front Pharmacol 2021;12:711126. [PMID: 34447310 DOI: 10.3389/fphar.2021.711126] [Reference Citation Analysis]
16 Zuo C, Xia M, Wu Q, Zhu H, Liu J, Liu C. Role of antiviral therapy in reducing recurrence and improving survival in hepatitis B virus-associated hepatocellular carcinoma following curative resection (Review). Oncol Lett 2015;9:527-34. [PMID: 25624883 DOI: 10.3892/ol.2014.2727] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
17 Yang C, Dong Z, Hong H, Dai B, Song F, Geng L, Lu J, Yang J, Sui C, Xu M. circFN1 Mediates Sorafenib Resistance of Hepatocellular Carcinoma Cells by Sponging miR-1205 and Regulating E2F1 Expression. Mol Ther Nucleic Acids 2020;22:421-33. [PMID: 33230446 DOI: 10.1016/j.omtn.2020.08.039] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
18 Wei L, Wang X, Lv L, Liu J, Xing H, Song Y, Xie M, Lei T, Zhang N, Yang M. The emerging role of microRNAs and long noncoding RNAs in drug resistance of hepatocellular carcinoma. Mol Cancer. 2019;18:147. [PMID: 31651347 DOI: 10.1186/s12943-019-1086-z] [Cited by in Crossref: 97] [Cited by in F6Publishing: 107] [Article Influence: 32.3] [Reference Citation Analysis]
19 de Souza PC, Ranjan A, Towner RA. Nanoformulations for therapy of pancreatic and liver cancers. Nanomedicine 2015;10:1515-34. [DOI: 10.2217/nnm.14.231] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
20 Alqahtani A, Khan Z, Alloghbi A, Said Ahmed TS, Ashraf M, Hammouda DM. Hepatocellular Carcinoma: Molecular Mechanisms and Targeted Therapies. Medicina (Kaunas) 2019;55:E526. [PMID: 31450841 DOI: 10.3390/medicina55090526] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 10.0] [Reference Citation Analysis]
21 Mlynarsky L, Menachem Y, Shibolet O. Treatment of hepatocellular carcinoma: Steps forward but still a long way to go. World J Hepatol 2015; 7(3): 566-574 [PMID: 25848480 DOI: 10.4254/wjh.v7.i3.566] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
22 Yan MD, Yao CJ, Chow JM, Chang CL, Hwang PA, Chuang SE, Whang-Peng J, Lai GM. Fucoidan Elevates MicroRNA-29b to Regulate DNMT3B-MTSS1 Axis and Inhibit EMT in Human Hepatocellular Carcinoma Cells. Mar Drugs 2015;13:6099-116. [PMID: 26404322 DOI: 10.3390/md13106099] [Cited by in Crossref: 54] [Cited by in F6Publishing: 53] [Article Influence: 7.7] [Reference Citation Analysis]
23 Peck-Radosavljevic M. Drug therapy for advanced-stage liver cancer. Liver Cancer 2014;3:125-31. [PMID: 24945003 DOI: 10.1159/000343868] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 5.1] [Reference Citation Analysis]
24 Osaki Y, Nishikawa H. Treatment for hepatocellular carcinoma in Japan over the last three decades: Our experience and published work review. Hepatol Res 2015;45:59-74. [PMID: 24965914 DOI: 10.1111/hepr.12378] [Cited by in Crossref: 52] [Cited by in F6Publishing: 56] [Article Influence: 6.5] [Reference Citation Analysis]
25 Fang Y, Yang W, Cheng L, Meng F, Zhang J, Zhong Z. EGFR-targeted multifunctional polymersomal doxorubicin induces selective and potent suppression of orthotopic human liver cancer in vivo. Acta Biomater 2017;64:323-33. [PMID: 29030307 DOI: 10.1016/j.actbio.2017.10.013] [Cited by in Crossref: 49] [Cited by in F6Publishing: 49] [Article Influence: 9.8] [Reference Citation Analysis]
26 Hsu CH, Shen YC, Shao YY, Hsu C, Cheng AL. Sorafenib in advanced hepatocellular carcinoma: current status and future perspectives. J Hepatocell Carcinoma 2014;1:85-99. [PMID: 27508178 DOI: 10.2147/JHC.S45040] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
27 Kießling MK, Nicolay JP, Schlör T, Klemke CD, Süss D, Krammer PH, Gülow K. NRAS mutations in cutaneous T cell lymphoma (CTCL) sensitize tumors towards treatment with the multikinase inhibitor Sorafenib. Oncotarget 2017;8:45687-97. [PMID: 28537899 DOI: 10.18632/oncotarget.17669] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
28 Giovannini C, Fornari F, Dallo R, Gagliardi M, Nipoti E, Vasuri F, Coadă CA, Ravaioli M, Bolondi L, Gramantieri L. MiR-199-3p replacement affects E-cadherin expression through Notch1 targeting in hepatocellular carcinoma. Acta Histochem 2018;120:95-102. [PMID: 29249451 DOI: 10.1016/j.acthis.2017.12.004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
29 Li Y, Zhang Y, Zhang S, Huang D, Li B, Liang G, Wu Y, Jiang Q, Li L, Lin C, Wei Z, Meng L. circRNA circARNT2 Suppressed the Sensitivity of Hepatocellular Carcinoma Cells to Cisplatin by Targeting the miR-155-5p/PDK1 Axis. Mol Ther Nucleic Acids 2021;23:244-54. [PMID: 33425483 DOI: 10.1016/j.omtn.2020.08.037] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
30 Nishida N, Kudo M. Alteration of Epigenetic Profile in Human Hepatocellular Carcinoma and Its Clinical Implications. Liver Cancer 2014;3:417-27. [PMID: 26280003 DOI: 10.1159/000343860] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
31 Gao JJ, Shi ZY, Xia JF, Inagaki Y, Tang W. Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma. World J Gastroenterol 2015; 21(42): 12059-12070 [PMID: 26576091 DOI: 10.3748/wjg.v21.i42.12059] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 33] [Article Influence: 4.6] [Reference Citation Analysis]
32 Faltermeier C, Busuttil RW, Zarrinpar A. A Surgical Perspective on Targeted Therapy of Hepatocellular Carcinoma. Diseases 2015;3:221-52. [PMID: 28943622 DOI: 10.3390/diseases3040221] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
33 Chen X, Yan N. Stachydrine inhibits TGF-β1-induced epithelial-mesenchymal transition in hepatocellular carcinoma cells through the TGF-β/Smad and PI3K/Akt/mTOR signaling pathways. Anticancer Drugs 2021;32:786-92. [PMID: 33675608 DOI: 10.1097/CAD.0000000000001066] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Kaltenecker D, Themanns M, Mueller KM, Spirk K, Suske T, Merkel O, Kenner L, Luís A, Kozlov A, Haybaeck J, Müller M, Han X, Moriggl R. Hepatic growth hormone - JAK2 - STAT5 signalling: Metabolic function, non-alcoholic fatty liver disease and hepatocellular carcinoma progression. Cytokine 2019;124:154569. [PMID: 30389231 DOI: 10.1016/j.cyto.2018.10.010] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
35 Singh AR, Joshi S, Burgoyne AM, Sicklick JK, Ikeda S, Kono Y, Garlich JR, Morales GA, Durden DL. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma. Mol Cancer Ther 2016;15:2553-62. [PMID: 27496136 DOI: 10.1158/1535-7163.MCT-15-0976] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
36 Kawaguchi T, Kodama T, Hikita H, Makino Y, Saito Y, Tanaka S, Shimizu S, Sakamori R, Miyagi T, Wada H, Nagano H, Hiramatsu N, Tatsumi T, Takehara T. Synthetic lethal interaction of combined CD26 and Bcl-xL inhibition is a powerful anticancer therapy against hepatocellular carcinoma. Hepatol Res 2015;45:1023-33. [PMID: 25297967 DOI: 10.1111/hepr.12434] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
37 Delire B, Stärkel P. The Ras/MAPK pathway and hepatocarcinoma: pathogenesis and therapeutic implications. Eur J Clin Invest 2015;45:609-23. [PMID: 25832714 DOI: 10.1111/eci.12441] [Cited by in Crossref: 102] [Cited by in F6Publishing: 100] [Article Influence: 14.6] [Reference Citation Analysis]
38 Wang Z, Jiang C, Chen W, Zhang G, Luo D, Cao Y, Wu J, Ding Y, Liu B. Baicalein induces apoptosis and autophagy via endoplasmic reticulum stress in hepatocellular carcinoma cells. Biomed Res Int. 2014;2014:732516. [PMID: 24995326 DOI: 10.1155/2014/732516] [Cited by in Crossref: 17] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
39 Shaaban S, Negm A, Ibrahim EE, Elrazak AA. Chemotherapeutic agents for the treatment of hepatocellular carcinoma: efficacy and mode of action. Oncol Rev 2014;8:246. [PMID: 25992234 DOI: 10.4081/oncol.2014.246] [Cited by in Crossref: 15] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
40 Granito A, Marinelli S, Terzi E, Piscaglia F, Renzulli M, Venerandi L, Benevento F, Bolondi L. Metronomic capecitabine as second-line treatment in hepatocellular carcinoma after sorafenib failure. Dig Liver Dis. 2015;47:518-522. [PMID: 25861840 DOI: 10.1016/j.dld.2015.03.010] [Cited by in Crossref: 39] [Cited by in F6Publishing: 30] [Article Influence: 5.6] [Reference Citation Analysis]
41 Liu J, Jin H, Tian H, Lian G, Chen S, Li J, Zhang X, Ma D. Anaplastic lymphoma kinase protein expression predicts micrometastases and prognosis for patients with hepatocellular carcinoma. Oncol Lett 2016;11:213-23. [PMID: 26870191 DOI: 10.3892/ol.2015.3859] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
42 Ewald F, Nörz D, Grottke A, Bach J, Herzberger C, Hofmann BT, Nashan B, Jücker M. Vertical Targeting of AKT and mTOR as Well as Dual Targeting of AKT and MEK Signaling Is Synergistic in Hepatocellular Carcinoma. J Cancer 2015;6:1195-205. [PMID: 26535060 DOI: 10.7150/jca.12452] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]
43 Zeng T, Luo L, Huang Y, Ye X, Lin J. Upregulation of miR-138 Increases Sensitivity to Cisplatin in Hepatocellular Carcinoma by Regulating EZH2. Biomed Res Int 2021;2021:6665918. [PMID: 33748276 DOI: 10.1155/2021/6665918] [Reference Citation Analysis]
44 Burak KW, Sherman M. Hepatocellular carcinoma: Consensus, controversies and future directions. A report from the Canadian Association for the Study of the Liver Hepatocellular Carcinoma Meeting. Can J Gastroenterol Hepatol. 2015;29:178-184. [PMID: 25965437 DOI: 10.1155/2015/824263] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
45 Wang H, Yang J, Zhang K, Liu J, Li Y, Su W, Song N. Advances of Fibroblast Growth Factor/Receptor Signaling Pathway in Hepatocellular Carcinoma and its Pharmacotherapeutic Targets. Front Pharmacol 2021;12:650388. [PMID: 33935756 DOI: 10.3389/fphar.2021.650388] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
46 Daoudaki M, Fouzas I. Hepatocellular carcinoma. Wien Med Wochenschr 2014;164:450-5. [PMID: 25182146 DOI: 10.1007/s10354-014-0296-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
47 Llovet JM, Villanueva A, Lachenmayer A, Finn RS. Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol 2015;12:408-24. [PMID: 26054909 DOI: 10.1038/nrclinonc.2015.103] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
48 Bouattour M, Payancé A, Wassermann J. Evaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imaging. World J Hepatol 2015; 7(20): 2245-2263 [PMID: 26380650 DOI: 10.4254/wjh.v7.i20.2245] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]